文献速递消化、代谢与肾脏急症

索格列净联合胰岛素治疗1型糖尿病患者的疗效与安全性

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
PubMed 文献 · N Engl J Med · 2017-09-13
一句话结论在胰岛素治疗的1型糖尿病患者中,加用索格列净400 mg/日可使更多患者糖化血红蛋白<7.0%且无严重低血糖或糖尿病酮症酸中毒,但糖尿病酮症酸中毒发生率更高。

这项3期双盲试验在全球133个中心随机分配1402例接受胰岛素(泵或注射)治疗的1型糖尿病患者,分别接受索格列净400 mg/日或安慰剂治疗24周。主要终点为第24周糖化血红蛋白<7.0%且随机分组后无严重低血糖或糖尿病酮症酸中毒事件。索格列净组主要终点达成比例显著高于安慰剂组(28.6% vs 15.2%,P<0.001)。索格列净组糖化血红蛋白、体重、收缩压和每日平均餐时胰岛素剂量较基线的下降均显著大于安慰剂组,但糖尿病酮症酸中毒发生率也更高(3.0% vs 0.6%)。

要点

  • 索格列净组主要终点(第24周HbA1c<7.0%且无严重低血糖或DKA)达成率28.6%(200/699),安慰剂组15.2%(107/703),P<0.001。
  • 索格列净组较安慰剂组糖化血红蛋白多降低0.46个百分点,体重多降低2.98 kg,收缩压多降低3.5 mm Hg,每日平均餐时胰岛素剂量多减少2.8 U/日(所有比较P≤0.002)。
  • 严重低血糖发生率索格列净组3.0%(21例)与安慰剂组2.4%(17例)相似。
  • 血糖≤55 mg/dL(3.1 mmol/L)的有记录低血糖发生率索格列净组显著低于安慰剂组。
  • 糖尿病酮症酸中毒发生率索格列净组3.0%(21例)高于安慰剂组0.6%(4例)。

适用人群与场景

  • 接受任何胰岛素治疗(泵或注射)的1型糖尿病患者,年龄等纳入标准原文未详述。
  • 全球133个中心参与的3期双盲试验人群。

诊断标准与关键阈值

  • 主要终点:第24周糖化血红蛋白水平低于7.0%,且随机分组后无严重低血糖或糖尿病酮症酸中毒事件。
  • 有记录低血糖定义:血糖水平55 mg/dL(3.1 mmol/L)或以下。

处置流程与药物剂量

  • 索格列净400 mg/日口服,联合胰岛素治疗,疗程24周。
  • 对照为安慰剂。

红旗征与不能漏的情况

  • 糖尿病酮症酸中毒:索格列净组发生率3.0%(21例),安慰剂组0.6%(4例),索格列净组更高。

研究设计与关键结果

  • 3期双盲试验,全球133个中心,随机分配1402例1型糖尿病患者,索格列净400 mg/日组699例、安慰剂组703例,治疗24周。
  • 主要终点达成率:索格列净组28.6%(200/699)vs 安慰剂组15.2%(107/703),P<0.001。
  • 糖化血红蛋白较基线最小二乘均值变化:索格列净组较安慰剂组多降低0.46个百分点。
  • 体重较基线最小二乘均值变化:索格列净组较安慰剂组多降低2.98 kg。
  • 收缩压较基线最小二乘均值变化:索格列净组较安慰剂组多降低3.5 mm Hg。
  • 每日平均餐时胰岛素剂量较基线最小二乘均值变化:索格列净组较安慰剂组多减少2.8 U/日(所有比较P≤0.002)。
  • 严重低血糖:索格列净组3.0%(21例)vs 安慰剂组2.4%(17例),相似。
  • 血糖≤55 mg/dL(3.1 mmol/L)的有记录低血糖发生率索格列净组显著低于安慰剂组。

证据类型、等级与局限

  • 证据类型:3期随机双盲安慰剂对照试验。
  • 试验注册号:inTandem3,ClinicalTrials.gov NCT02531035;由Lexicon Pharmaceuticals资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在胰岛素治疗的1型糖尿病患者中,加用索格列净400 mg/日可提高达到糖化血红蛋白<7.0%且无严重低血糖或糖尿病酮症酸中毒的患者比例,但需注意糖尿病酮症酸中毒发生率更高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes.

METHODS: In this phase 3, double-blind trial, which was conducted at 133 centers worldwide, we randomly assigned 1402 patients with type 1 diabetes who were receiving treatment with any insulin therapy (pump or injections) to receive sotagliflozin (400 mg per day) or placebo for 24 weeks. The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, with no episodes of severe hypoglycemia or diabetic ketoacidosis after randomization. Secondary end points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressure, and mean daily bolus dose of insulin.

RESULTS: A significantly larger proportion of patients in the sotagliflozin group than in the placebo group achieved the primary end point (200 of 699 patients [28.6%] vs. 107 of 703 [15.2%], P<0.001). The least-squares mean change from baseline was significantly greater in the sotagliflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points), weight (-2.98 kg), systolic blood pressure (-3.5 mm Hg), and mean daily bolus dose of insulin (-2.8 units per day) (P≤0.002 for all comparisons). The rate of severe hypoglycemia was similar in the sotagliflozin group and the placebo group (3.0% [21 patients] and 2.4% [17], respectively). The rate of documented hypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per liter) or below was significantly lower in the sotagliflozin group than in the placebo group. The rate of diabetic ketoacidosis was higher in the sotagliflozin group than in the placebo group (3.0% [21 patients] and 0.6% [4], respectively).

CONCLUSIONS: Among patients with type 1 diabetes who were receiving insulin, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe hypoglycemia or diabetic ketoacidosis was larger in the group that received sotagliflozin than in the placebo group. However, the rate of diabetic ketoacidosis was higher in the sotagliflozin group. (Funded by Lexicon Pharmaceuticals; inTandem3 ClinicalTrials.gov number, NCT02531035 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Garg SK, Henry RR, Banks P, et al. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017. PMID: 28899222. doi:10.1056/NEJMoa1708337

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。